1 / 36

Spotlight on Emerging Agents for Myeloproliferative Neoplasms

Spotlight on Emerging Agents for Myeloproliferative Neoplasms. Myeloproliferative Neoplasms (MPNs). Main Goal in PV Therapy: Control Thrombotic Events. Management of High-Risk PV. ET -- Current Therapy. MF – Current Treatment. Unmet Needs in MPNs. Novel Agents in Development.

rowland
Télécharger la présentation

Spotlight on Emerging Agents for Myeloproliferative Neoplasms

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spotlight on Emerging Agents for Myeloproliferative Neoplasms

  2. Myeloproliferative Neoplasms (MPNs)

  3. Main Goal in PV Therapy: Control Thrombotic Events

  4. Management of High-Risk PV

  5. ET -- Current Therapy

  6. MF – Current Treatment

  7. Unmet Needs in MPNs

  8. Novel Agents in Development

  9. JAKARTA: Fedratinib (SAR302503) Phase 3 Study in Intermediate-2 or High-Risk MF

  10. JAKARTA: Spleen Volume Response, Primary Endpoint, Primary and Secondary Analyses, ITT

  11. JAKARTA-2: Single-Arm, Multicenter, Open-Label Study (NCT01523171)[a]

  12. JAKARTA-2 Results

  13. Toxicity of Fedratinib in JAKARTA-1 and JAKARTA-2

  14. Re-Assessment of JAKARTA-2[a]

  15. Momelotinib

  16. Pacritinib: PERSIST-1 and PERSIST-2 Design

  17. Pacritinib Splenic Volume Responses

  18. PERSIST-2 Overall Survival

  19. Patient Case #1

  20. Proposed Positioning of JAK Inhibitors in Myelofibrosis

  21. Emerging Combination With JAK Inhibitors

  22. Patient Case #2

  23. Patient Case #2 (cont)

  24. Treatment Options After Failure of Ruxolitinib

  25. Imetelstat: Phase 2 Study in MF

  26. Patient Case #3

  27. Using Interferon-Alpha for PV

  28. Novel Therapies for PV

  29. Ropeginterferon vs Hydroxyurea: Findings From CONTI-PV

  30. Shifting Goals of MF Therapy With Activin Ligand Traps

  31. Sotatercept for Anemia in MF: Phase II Results

  32. Other Investigational Agents in MPN Therapy

  33. Abbreviations

  34. Abbreviations (cont)

  35. Abbreviations (cont)

More Related